444 related articles for article (PubMed ID: 35830711)
1. siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.
Sargazi S; Arshad R; Ghamari R; Rahdar A; Bakhshi A; Karkan SF; Ajalli N; Bilal M; Díez-Pascual AM
Cell Biol Int; 2022 Sep; 46(9):1320-1344. PubMed ID: 35830711
[TBL] [Abstract][Full Text] [Related]
2. The emerging potential of siRNA nanotherapeutics in treatment of arthritis.
Kumari A; Kaur A; Aggarwal G
Asian J Pharm Sci; 2023 Sep; 18(5):100845. PubMed ID: 37881798
[TBL] [Abstract][Full Text] [Related]
3. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
4. Nanotherapeutics for the Treatment of Cancer and Arthritis.
Patel P; Meghani N; Kansara K; Kumar A
Curr Drug Metab; 2019; 20(6):430-445. PubMed ID: 30479211
[TBL] [Abstract][Full Text] [Related]
5. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
6. Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model.
Jansen MAA; Klausen LH; Thanki K; Lyngsø J; Skov Pedersen J; Franzyk H; Nielsen HM; van Eden W; Dong M; Broere F; Foged C; Zeng X
Eur J Pharm Biopharm; 2019 Sep; 142():38-48. PubMed ID: 31199978
[TBL] [Abstract][Full Text] [Related]
7. siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery.
He C; Yue H; Xu L; Liu Y; Song Y; Tang C; Yin C
Acta Biomater; 2020 Feb; 103():213-222. PubMed ID: 31812844
[TBL] [Abstract][Full Text] [Related]
8. Lipid-Based Nanocarriers for RNA Delivery.
Xue HY; Guo P; Wen WC; Wong HL
Curr Pharm Des; 2015; 21(22):3140-7. PubMed ID: 26027572
[TBL] [Abstract][Full Text] [Related]
9. Bioengineered nanoparticles for siRNA delivery.
Kozielski KL; Tzeng SY; Green JJ
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2013; 5(5):449-68. PubMed ID: 23821336
[TBL] [Abstract][Full Text] [Related]
10. Small interfering RNA-based nanotherapeutics for treating skin-related diseases.
Chang YT; Huang TH; Alalaiwe A; Hwang E; Fang JY
Expert Opin Drug Deliv; 2023 Jun; 20(6):757-772. PubMed ID: 37088710
[TBL] [Abstract][Full Text] [Related]
11. Nanocarrier Mediated siRNA Delivery Targeting Stem Cell Differentiation.
Fernandes F; Kotharkar P; Chakravorty A; Kowshik M; Talukdar I
Curr Stem Cell Res Ther; 2020; 15(2):155-172. PubMed ID: 31789134
[TBL] [Abstract][Full Text] [Related]
12. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
13. siRNA applications in nanomedicine.
Tokatlian T; Segura T
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(3):305-15. PubMed ID: 20135697
[TBL] [Abstract][Full Text] [Related]
14. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
Sivakumar P; Kim S; Kang HC; Shim MS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy.
Zhang J; Chen B; Gan C; Sun H; Zhang J; Feng L
Int J Nanomedicine; 2023; 18():7605-7635. PubMed ID: 38106451
[TBL] [Abstract][Full Text] [Related]
16. Protein-Based Nanocarriers and Nanotherapeutics for Infection and Inflammation.
Nagar N; Naidu G; Mishra A; Poluri KM
J Pharmacol Exp Ther; 2024 Jan; 388(1):91-109. PubMed ID: 37699711
[TBL] [Abstract][Full Text] [Related]
17. Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery.
Prabhakar N; Zhang J; Desai D; Casals E; Gulin-Sarfraz T; Näreoja T; Westermarck J; Rosenholm JM
Int J Nanomedicine; 2016; 11():6591-6608. PubMed ID: 27994460
[TBL] [Abstract][Full Text] [Related]
18. Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat.
Amadio M; Pascale A; Cupri S; Pignatello R; Osera C; D Agata V; D Amico AG; Leggio GM; Ruozi B; Govoni S; Drago F; Bucolo C
Pharmacol Res; 2016 Sep; 111():713-720. PubMed ID: 27475885
[TBL] [Abstract][Full Text] [Related]
19. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
[TBL] [Abstract][Full Text] [Related]
20. Engineering of Solid Dosage Forms of siRNA-Loaded Lipidoid-Polymer Hybrid Nanoparticles Using a Quality-by-Design Approach.
Lokras A; Foged C; Thakur A
Methods Mol Biol; 2021; 2282():137-157. PubMed ID: 33928574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
